Research Nester released a report titled “Anti-Obesity Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global anti-obesity drugs market in terms of market segmentation by mechanism of action, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The market for anti-obesity drugs is anticipated to record a CAGR of around 21% over the forecast period, i.e., 2019-2027. The market is segmented by mechanism of action, by distribution channel and by region, out of which, the mechanism of action segment is further bifurcated into peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. Both the segments are estimated to grow in future on account of the rising demand for these drugs. The drugs which include the central nervous system as a part of their mechanism of action are centrally acting anti-obesity drugs while others are peripherally acting anti-obesity drugs.

The market in North America is anticipated to hold the largest share in the anti-obesity drugs market. This can be attributed to the high prevalence of obesity in the region, especially in the United States. The growing healthcare expenditure and increasing approval of anti-obesity drugs further contribute towards the market growth. On the other hand, the market in the Asia Pacific region is predicted to grow at the highest rate during the forecast period on account of growing incidences of diabetes and other such disorders which are associated with obesity.

Increasing Health Consciousness among People to Expand the Market

Growing awareness among people about the health risks associated with obesity such as cardiovascular disease, diabetes and others are anticipated to significantly drive the market growth over the forecast period. Moreover, the adoption of healthy food habits and measures taken to decrease the consumption of fatty foods is further predicted to add to the market growth. However, the side effects of anti-obesity drugs including stroke, mental illness and other undesired health conditions are estimated to hamper the market growth during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global anti-obesity drugs market which includes company profiling of F. Hoffmann-La Roche (SWX: ROG), GlaxoSmithKline plc. (LON: GSK), Takeda Pharmaceutical Company Limited (TYO: 4502), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Boehringer Ingelheim International GmbH, Eisai Co., Ltd. (TYO: 4523), Novo Nordisk (CPH: NOVO-B), Pfizer Inc. (NYSE: PFE), Rhythm Pharmaceuticals, Inc. and Shionogi Inc. (TYO: 4507). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global anti-obesity drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.